340B PATIENTS Act of 2025

Bill Summary: 340B PATIENTS Act of 2025 (S. 2372)

Overview

The 340B Pharmaceutical Access To Invest in Essential, Needed Treatments & Support Act of 2025 is designed to protect and clarify the rights of healthcare providers participating in the 340B drug discount program. The bill specifically targets the ability of "covered entities" (such as hospitals and clinics) to use contract pharmacies to dispense discounted medications to their patients without interference from drug manufacturers.

Purpose and Intent

The primary goal of the bill is to prevent pharmaceutical manufacturers from restricting how covered entities distribute 340B drugs. The legislation asserts that the 340B program's intent is to help providers stretch scarce resources to reach more patients, and that contract pharmacies are essential for this—particularly for specialty drugs (e.g., for cancer or multiple sclerosis) that require specialized handling or mail-order delivery.

Key Provisions

1. Protection of Dispensing Methods

The bill amends the Public Health Service Act to explicitly state that drug manufacturers must offer discount pricing regardless of the manner or location in which the drug is dispensed. This includes drugs dispensed through contractual relationships with third-party pharmacies.

2. Prohibition of Manufacturer Conditions

The Act prohibits drug manufacturers from imposing conditions on the purchase or use of discounted drugs that would:
* Limit where drugs are delivered, administered, or dispensed.
* Require the submission of claims data or other information not required of other customers.
* Discourage providers from using the program or undermine its objectives.
* Impose requirements that do not reflect customary business practices.
* Fail to receive prior approval from the Secretary of Health and Human Services (HHS).

3. Enforcement and Penalties

To ensure compliance, the bill introduces significant financial deterrents for manufacturers who intentionally violate these rules:
* Civil Monetary Penalties: Manufacturers found in violation (other than overcharging) can be fined up to $2,000,000 per day, per violation.
* Secretary Oversight: The Secretary of HHS is tasked with establishing the standards for these penalties within 180 days of the bill's enactment.
* Claims Process: The Secretary must create a regulatory process within 180 days to allow covered entities to formally assert claims of violations against manufacturers.

Who is Affected?

• Covered Entities (Hospitals, Clinics, Health Centers): These providers gain greater legal certainty and protection when using contract pharmacies to serve their patients.
• Drug Manufacturers: Pharmaceutical companies would be legally barred from restricting 340B drug distribution to contract pharmacies and would face steep daily fines for non-compliance.
• Patients: Particularly those requiring specialty drugs, patients may see more consistent access to affordable medications through their provider's chosen pharmacy networks.

Timeline and Procedural Status

• Introduced: July 22, 2025.
• Current Status: Referred to the Senate Committee on Health, Education, Labor, and Pensions.
• Implementation: If passed, the Secretary of HHS must promulgate regulations regarding penalties and violation claims within 180 days of enactment.